| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701310 | European Journal of Surgical Oncology (EJSO) | 2017 | 8 Pages |
Abstract
Perioperative chemotherapy for GEJ adenocarcinoma leads to increased survival in good responders (34%) as compared to surgery alone. Poor responders had no survival benefit and developed more recurrences, which underlines the importance of the search for predictive biological or radiological markers to predict or assess chemotherapy sensitivity.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
K. Parry, P.S.N. van Rossum, N. Haj Mohammad, J.P. Ruurda, R. van Hillegersberg,